362703-57-9

Basic information

• Product Name: METHYL DL-2-(1-BOC-PIPERIDIN-4-YL)-BETA-GLYCINATE
• Synonyms: tert-butyl 4-amino-4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate;4-Piperidineacetic acid, 4-amino-1-[(1,1-dimethylethoxy)carbonyl]-, methyl ester;4-Amino-1-[(tert-butoxy)carbonyl]-4-piperidineacetic acid methyl ester;tert-Butyl 4-amino-4-(2-methoxy-2-oxoethyl)
• CAS NO: 362703-57-9
• Molecular Formula: C₁₃H₂₄N₂O₄
• Molecular Weight: 272.343
• Mol File: 362703-57-9.mol

Chemical Properties

• Boiling Point: 348℃
• Flash Point: 165℃
• Appearance: /
• Density: 1.096
• Vapor Pressure: 5.04E-05mmHg at 25°C
• Refractive Index: 1.48
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
• CAS DataBase Reference: METHYL DL-2-(1-BOC-PIPERIDIN-4-YL)-BETA-GLYCINATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL DL-2-(1-BOC-PIPERIDIN-4-YL)-BETA-GLYCINATE(362703-57-9)
• EPA Substance Registry System: METHYL DL-2-(1-BOC-PIPERIDIN-4-YL)-BETA-GLYCINATE(362703-57-9)

Safety Data

• Hazardous Substances Data: 362703-57-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
METHYL DL-2-(1-BOC-PIPERIDIN-4-YL)-BETA-GLYCINATE is used as a building block for the development of new pharmaceuticals, particularly for the synthesis of SHP2 protein tyrosine phosphatase inhibitors. These inhibitors are of interest in the treatment of various diseases, including cancer and inflammatory disorders, due to their ability to modulate key signaling pathways involved in these conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, METHYL DL-2-(1-BOC-PIPERIDIN-4-YL)-BETA-GLYCINATE is used as a key intermediate in the synthesis of bioactive molecules. Its unique structure allows for the attachment of various functional groups, enabling the creation of diverse drug candidates with potential therapeutic applications.
Used in Drug Design and Optimization:
METHYL DL-2-(1-BOC-PIPERIDIN-4-YL)-BETA-GLYCINATE is utilized in drug design and optimization processes to improve the potency, selectivity, and pharmacokinetic properties of drug candidates. By incorporating this compound into the molecular structure, researchers can fine-tune the properties of new drugs to enhance their therapeutic efficacy and safety profiles.

InChI:InChI=1/C13H24N2O4/c1-12(2,3)19-11(17)15-7-5-13(14,6-8-15)9-10(16)18-4/h5-9,14H2,1-4H3

Upstream product

• 1159983-30-8 4-amino-4-carboxymethylpiperidine-1-carboxylic acid tert-butyl ester 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 169206-65-9 1-tert-butoxycarbonyl-4-[(methoxycarbonyl)methylene]piperidine 

Downstream Products

• 362703-66-0 {1-methyl-4-[4-(2-methyl-quinolin-4-ylmethoxy)-benzoylamino]-piperidin-4-yl}-acetic acid methyl ester 
• 362703-59-1 {4-[4-(2-methyl-quinolin-4-ylmethoxy)-benzoylamino]-piperidin-4-yl}-acetic acid methyl ester 
• 362697-55-0 N-{4-[2-(hydroxyamino)-2-oxoethyl]-4-piperidinyl}-4-[(2-methyl-4-quinolinyl)methoxy]benzamide 
• 362703-78-4 {1-ethyl-4-[4-(2-methyl-quinolin-4-ylmethoxy)-benzoylamino]-piperidin-4-yl}-acetic acid methyl ester 
• 362703-68-2 {1-acetyl-4-[4-(2-methyl-quinolin-4-ylmethoxy)-benzoylamino]-piperidin-4-yl}-acetic acid methyl ester 
• 362703-61-5 {4-[4-(2-methyl-quinolin-4-ylmethoxy)-benzoylamino]-1-propyl-piperidin-4-yl}-acetic acid methyl ester 
• 362703-62-6 {1-methanesulfonyl-4-[4-(2-methyl-quinolin-4-ylmethoxy)-benzoylamino]-piperidin-4-yl}-acetic acid methyl ester 
• 362704-28-7 {1-(2,2-dimethyl-propyl)-4-[4-(2-methyl-quinolin-4-ylmethoxy)-benzoylamino]-piperidin-4-yl}-acetic acid methyl ester 
• 362703-89-7 {1-isobutyryl-4-[4-(2-methyl-quinolin-4-ylmethoxy)-benzoylamino]-piperidin-4-yl}-acetic acid methyl ester 
• 362703-70-6 {1-(2-fluoro-ethyl)-4-[4-(2-methyl-quinolin-4-ylmethoxy)-benzoylamino]-piperidin-4-yl}-acetic acid methyl ester 
• 362703-85-3 {4-[4-(2-methyl-quinolin-4-ylmethoxy)-benzoylamino]-1-propionyl-piperidin-4-yl}-acetic acid methyl ester 
• 362703-63-7 {1-(2,2-dimethyl-propionyl)-4-[4-(2-methyl-quinolin-4-ylmethoxy)-benzoylamino]-piperidin-4-yl}-acetic acid methyl ester 
• 362704-20-9 {1-benzyl-4-[4-(2-methyl-quinolin-4-ylmethoxy)-benzoylamino]-piperidin-4-yl}-acetic acid methyl ester 
• 362703-93-3 {1-(3-methyl-butyryl)-4-[4-(2-methyl-quinolin-4-ylmethoxy)-benzoylamino]-piperidin-4-yl}-acetic acid methyl ester 

Relevant articles and documents

Dual Nickel/Photoredox-Catalyzed Deaminative Cross-Coupling of Sterically Hindered Primary Amines

We report a method to activate α-3° amines for deaminative arylation via condensation with an electron-rich aldehyde and merge this reactivity with nickel metallaphotoredox to generate benzylic quaternary centers, a common motif in pharmaceuticals and natural products. The reaction is accelerated by added ammonium salts. Evidence is provided in support of two roles for the additive: inhibition of nickel black formation and acceleration of the overall reaction rate. We demonstrate a robust scope of amine and haloarene coupling partners and show an expedited synthesis of ALK2 inhibitors.

3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND

There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I'): (in the above-mentioned general formula (I'), W, Y, R2, R3, R4, and Y4 are as described hereinabove), or pharmaceutically acceptable salts thereof.

Synthesis and structure-activity relationship of a novel, achiral series of TNF-α converting enzyme inhibitors

A novel series of achiral TNF-α converting enzyme (TACE) inhibitors has been discovered. These compounds exhibited activities from 0.35 to 11 nM in a porcine TACE assay and inhibited TNF-α production in an LPS-stimulated whole blood assay with an IC5

Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha

The present application describes novel β-amino acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, X, Z, Ua, Xa, Ya, Za, R1, R2, R3